Adicet Bio Inc (ACET) Stock Price, Quote & News

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 503 9095

Website: www.adicetbio.com

Address:

131 Dartmouth Street, 3rd Floor, Boston, United States

BullyMCBullface Aug. 11 at 10:00 PM

$ACET listened to the talk in my car; this guy knows where he is talking about and was a confident speaker with very specific and clear answers. Let’s hope he doesn’t believe in fairytales

0 · Reply

BioTechChap Aug. 11 at 6:15 PM

$ACET CMO leaves the company disorderly at the cusp of a major inflection point. SMH, as bearish as it can get. Of course no mention of this transition during today's Canaccord conference session.

0 · Reply

aletz Aug. 7 at 6:49 PM

$ACET 2H 2026, a bunch of catalysts are coming after a long wait. It'll be exciting to see the real efficacy data and regulatory pathway. Started a long position yesterday. $INAB , another gamma delta t cel engager currently pending preclinical data. SP beaten down lately.

0 · Reply

91aprilfool Aug. 7 at 5:35 PM

$ACET @metalcook nice try! The previous Chief Medical Officer, Dr. Francesco Galimi, left when his tenure concluded in December 2024. He was succeeded by Dr. Julie Maltzman, who was appointed as the new Chief Medical Officer effective January 13, 2025.

1 · Reply

metalcook Aug. 6 at 5:46 PM

$ACET so CMO left and management has delayed data. Whats up with the phase 3 plans? Seems clearly a problem here. These red flags are classic signals of bad management. I would guess durability is a problem

1 · Reply

anachartanalyst Aug. 6 at 2:03 PM

$ACET https://anachart.com/wp-content/uploads/2026/08/1786024972_soc-img.jpg

0 · Reply

Flowjob Aug. 5 at 8:28 PM

$ACET Data delayed to Q3, likely September imo GLTA

3 · Reply

rml360 Jul. 31 at 2:56 PM

$ACET where is the data? its august already jesus

1 · Reply

AGC_Trader Jul. 30 at 7:44 PM

$ACET Closing above the 200EMA on the daily chart at $8.98 would be great

1 · Reply

metalcook Jul. 24 at 3:27 PM

$ACET so market thinks results are a 0 and management is a 0 as they will burn the cash instead of a reorganization. Looks a lot like $NKTX

0 · Reply

Adicet Bio Transcript: Canaccord Genuity's 46th Annual Growth Conference

2026-08-06T10:53:16.000Z - 10 days ago

Adicet Bio price target lowered to $90 from $100 at Guggenheim

2026-08-05T20:52:47.000Z - 11 days ago

Adicet Bio reports Q2 EPS ($1.99), consensus ($1.64)

Aug 5, 2026, 4:15 PM EDT - 11 days ago

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aug 5, 2026, 4:00 PM EDT - 11 days ago

Adicet Bio Quarterly report: Q2 2026

Aug 5, 2026, 4:00 PM EDT - 11 days ago

Adicet Bio Earnings release: Q2 2026

Aug 1, 2026, 8:00 AM EDT - 15 days ago

Adicet Bio Slides: Investor presentation

Jul 21, 2026, 4:00 PM EDT - 26 days ago

Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

Jun 17, 2026, 5:00 PM EDT - 2 months ago

Adicet Bio Transcript: AGM 2026

Jun 4, 2026, 7:35 AM EDT - 2 months ago

Adicet Bio Transcript: Jefferies Global Healthcare Conference 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

2026-05-13T20:24:33.000Z - 3 months ago

Adicet Bio reports Q1 EPS ($1.88), consensus ($3.08)

May 13, 2026, 4:01 PM EDT - 3 months ago

Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

May 13, 2026, 4:00 PM EDT - 3 months ago

Adicet Bio Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 3 months ago

Adicet Bio Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Adicet Bio Slides: Investor presentation

2026-05-04T20:41:09.000Z - 3 months ago

Adicet Bio assumed with a Buy at Jefferies

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Adicet Bio Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Adicet Bio Proxy statement: Proxy filing

2026-03-23T10:10:51.000Z - 5 months ago

Adicet Bio price target lowered to $27 from $50 at H.C. Wainwright

2026-03-13T11:40:50.000Z - 5 months ago

Adicet Bio price target lowered to $100 from $128 at Guggenheim

2026-03-12T21:20:37.000Z - 5 months ago

Adicet Bio files $250M mixed securities shelf

Mar 12, 2026, 5:00 PM EDT - 5 months ago

Adicet Bio Annual report: Q4 2025

Mar 12, 2026, 5:00 PM EDT - 5 months ago

Adicet Bio Earnings release: Q4 2025

2026-03-12T20:05:37.000Z - 5 months ago

Adicet Bio reports Q4 EPS ($2.94), consensus ($2.99)

Mar 12, 2026, 4:00 PM EDT - 5 months ago

Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Adicet Bio Registration statement: Registration Filing

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Adicet Bio Slides: Investor presentation

Jan 30, 2026, 7:00 AM EST - 7 months ago

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-21T11:16:04.000Z - 7 months ago

Adicet Bio price target adjusted to $50 from $9 at H.C. Wainwright

Jan 7, 2026, 7:00 AM EST - 7 months ago

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

2026-01-06T11:26:03.000Z - 7 months ago

Adicet Bio price target lowered to $18 from $128 at Canaccord

2025-12-30T00:55:17.000Z - 8 months ago

Adicet Bio trading halted, news pending

Dec 26, 2025, 8:30 AM EST - 8 months ago

Adicet Bio Announces Reverse Stock Split

Nov 28, 2025, 2:23 PM EST - 9 months ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Nov 17, 2025, 7:00 AM EST - 9 months ago

Adicet Bio Proxy statement: Proxy Filing

Nov 11, 2025, 3:00 PM EST - 9 months ago

Adicet Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 4:01 PM EST - 10 months ago

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 5, 2025, 7:00 AM EST - 10 months ago

Adicet Bio Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Adicet Bio Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Adicet Bio Proxy statement: Proxy Filing

Oct 31, 2025, 4:59 PM EDT - 10 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 28, 2025, 7:00 AM EDT - 10 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

$Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)$

Oct 16, 2025, 7:00 AM EDT - 10 months ago

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Adicet Bio Transcript: Study Update

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Adicet Bio Press release: Study Update

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Adicet Bio Slides: Study Update

Oct 7, 2025, 7:01 AM EDT - 11 months ago

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Oct 7, 2025, 6:45 AM EDT - 11 months ago

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Sep 8, 2025, 4:30 PM EDT - 1 year ago

Adicet Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 1:30 PM EDT - 1 year ago

Adicet Bio Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 4:01 PM EDT - 1 year ago

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio Quarterly report: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Jul 24, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio Slides: Investor Presentation

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Adicet Bio Transcript: Jefferies Global Healthcare Conference 2025

May 21, 2025, 4:00 PM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 7, 2025, 1:30 PM EDT - 1 year ago

Adicet Bio Transcript: The Citizens JMP Life Sciences Conference 2025

May 6, 2025, 4:01 PM EDT - 1 year ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:00 PM EDT - 1 year ago

Adicet Bio Quarterly report: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Adicet Bio Earnings release: Q1 2025

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Adicet Bio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Adicet Bio Proxy statement: Proxy Filing

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Mar 31, 2025, 5:12 PM EDT - 1 year ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 6, 2025, 4:01 PM EST - 1 year ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 6, 2025, 3:00 PM EST - 1 year ago

Adicet Bio Annual report: Q4 2024

Mar 6, 2025, 3:00 PM EST - 1 year ago

Adicet Bio Earnings release: Q4 2024

Mar 6, 2025, 7:00 AM EST - 1 year ago

Adicet Bio Registration statement: Registration Filing

Mar 3, 2025, 7:00 AM EST - 1 year ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Feb 27, 2025, 7:00 AM EST - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Feb 5, 2025, 2:00 PM EST - 1 year ago

Adicet Bio Transcript: Guggenheim SMID Cap Biotech Conference

$Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement$

Feb 5, 2025, 7:10 AM EST - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Jan 29, 2025, 7:00 AM EST - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 8, 2025, 4:10 PM EST - 1 year ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Dec 19, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Nov 19, 2024, 7:30 AM EST - 1 year ago

Adicet Bio Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 4:00 PM EST - 1 year ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 16, 2024, 9:00 AM EST - 1 year ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 12, 2024, 3:00 PM EST - 1 year ago

Adicet Bio Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 4:00 PM EST - 1 year ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 5, 2024, 6:00 PM EST - 1 year ago

Adicet Bio Quarterly report: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Adicet Bio Earnings release: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in Upcoming Investor Conferences

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Sep 30, 2024, 4:30 PM EDT - 2 years ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 7:00 AM EDT - 2 years ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 19, 2024, 7:00 AM EDT - 2 years ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Sep 18, 2024, 8:00 PM EDT - 2 years ago

Adicet Bio Transcript: 9th Annual CAR-TCR U.S. Summit

Sep 18, 2024, 8:00 PM EDT - 2 years ago

Adicet Bio Slides: 9th Annual CAR-TCR U.S. Summit

Sep 10, 2024, 2:30 PM EDT - 2 years ago

Adicet Bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 27, 2024, 4:00 PM EDT - 2 years ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 7:00 AM EDT - 2 years ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 13, 2024, 10:30 AM EDT - 2 years ago

Adicet Bio Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 13, 2024, 10:30 AM EDT - 2 years ago

Adicet Bio Slides: FY 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Adicet Bio Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Adicet Bio Earnings release: Q2 2024

Jul 8, 2024, 7:00 AM EDT - 2 years ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Jun 5, 2024, 1:00 PM EDT - 2 years ago

Adicet Bio Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 7:00 AM EDT - 2 years ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

BullyMCBullface Aug. 11 at 10:00 PM

$ACET listened to the talk in my car; this guy knows where he is talking about and was a confident speaker with very specific and clear answers. Let’s hope he doesn’t believe in fairytales

0 · Reply

BioTechChap Aug. 11 at 6:15 PM

$ACET CMO leaves the company disorderly at the cusp of a major inflection point. SMH, as bearish as it can get. Of course no mention of this transition during today's Canaccord conference session.

0 · Reply

aletz Aug. 7 at 6:49 PM

0 · Reply

91aprilfool Aug. 7 at 5:35 PM

1 · Reply

metalcook Aug. 6 at 5:46 PM

1 · Reply

anachartanalyst Aug. 6 at 2:03 PM

$ACET https://anachart.com/wp-content/uploads/2026/08/1786024972_soc-img.jpg

0 · Reply

Flowjob Aug. 5 at 8:28 PM

$ACET Data delayed to Q3, likely September imo GLTA

3 · Reply

rml360 Jul. 31 at 2:56 PM

$ACET where is the data? its august already jesus

1 · Reply

AGC_Trader Jul. 30 at 7:44 PM

$ACET Closing above the 200EMA on the daily chart at $8.98 would be great

1 · Reply

metalcook Jul. 24 at 3:27 PM

$ACET so market thinks results are a 0 and management is a 0 as they will burn the cash instead of a reorganization. Looks a lot like $NKTX

0 · Reply

ajmrtxl Jul. 22 at 3:56 PM

$ACET 's latest data on SqueezeFinder

0 · Reply

BioTechChap Jul. 16 at 5:21 AM

$ACET FDA meeting minutes take up to 30 days, so we should expect an update before the end of the month latest. Assuming a combination of regulatory and data updates.

1 · Reply

metalcook Jul. 15 at 8:08 AM

$ACET if it doesnt come this week, 6 Aug is more likely. Hope they close shop amd return money to shareholders

1 · Reply

rml360 Jul. 14 at 8:08 PM

$ACET where is the data? wtf? anyone know anything?

0 · Reply

onononon Jul. 11 at 2:32 AM

$ACET they'll probably release the data once july options expire.

0 · Reply

metalcook Jul. 10 at 11:14 AM

$ACET there is alomst 0 volume. XBI is at all time highs. Something clearly wring here. Yes it is trading beneaty cash but bad management will burn cash fast. Market is expecting PR that will indicate stop CAR allogenic trials and begin phase 1 in prostate cancer which would validate the market price we are seeing now.

0 · Reply

AGC_Trader Jul. 9 at 1:52 PM

$ACET The $9.30 -$9.40 area is quite a resistance...I am curious to see what happens after it passes through it

2 · Reply

DCZ Jul. 8 at 3:33 PM

$ACET everything is dumping today on my list except this. News leak?

0 · Reply

BioTechChap Jul. 7 at 9:06 PM

$ACET

0 · Reply

metalcook Jul. 6 at 10:53 AM

$ACET release$ACET of data should be doNE ASAP!

0 · Reply

thebrockettman Jul. 2 at 10:38 PM

$ACET Idk what's happening but I like it! Above average volume most of this week! The 200d moving average is at $9.09 and we got so close to closing above that today. If we can stay above that the algos should start to participate too!

1 · Reply

AGC_Trader Jul. 2 at 2:14 PM

$ACET Something is moving...

0 · Reply

Market Cap	78.45M
Revenue (ttm)	0.00
Net Income (ttm)	-116.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	57,900
Avg Vol	86,394
Day's Range	N/A - N/A
Shares Out	9.36M
Stochastic %K	46%
Beta	1.60
Analysts	Strong Sell
Price Target	$33.17